Lucia Russo1, Harrison T Muturi1,2, Hilda E Ghadieh1, Simona S Ghanem1, Thomas A Bowman1, Hye Lim Noh3, Sezin Dagdeviren3, Godwin Y Dogbey2, Jason K Kim3, Garrett Heinrich2,4, Sonia M Najjar5,6,7. 1. Center for Diabetes and Endocrine Research, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA. 2. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Irvine Hall 229, 1 Ohio University, Athens, OH, 45701-2979, USA. 3. Division of Endocrinology, Metabolism and Diabetes, University of Massachusetts Medical School, Worcester, MA, USA. 4. Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA. 5. Center for Diabetes and Endocrine Research, College of Medicine and Life Sciences, University of Toledo, Toledo, OH, USA. najjar@ohio.edu. 6. Department of Biomedical Sciences, Heritage College of Osteopathic Medicine, Ohio University, Irvine Hall 229, 1 Ohio University, Athens, OH, 45701-2979, USA. najjar@ohio.edu. 7. Diabetes Institute, Heritage College of Osteopathic Medicine, Ohio University, Athens, OH, USA. najjar@ohio.edu.
Abstract
AIMS/HYPOTHESIS: The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) promotes insulin clearance. Mice with global null mutation (Cc1 -/-) or with liver-specific inactivation (L-SACC1) of Cc1 (also known as Ceacam1) gene display hyperinsulinaemia resulting from impaired insulin clearance, insulin resistance, steatohepatitis and obesity. Because increased lipolysis contributes to the metabolic phenotype caused by transgenic inactivation of CEACAM1 in the liver, we aimed to further investigate the primary role of hepatic CEACAM1-dependent insulin clearance in insulin and lipid homeostasis. To this end, we examined whether transgenic reconstitution of CEACAM1 in the liver of global Cc1 -/- mutant mice reverses their abnormal metabolic phenotype. METHODS: Insulin response was assessed by hyperinsulinaemic-euglycaemic clamp analysis and energy balance was analysed by indirect calorimetry. Mice were overnight-fasted and refed for 7 h to assess fatty acid synthase activity in the liver and the hypothalamus in response to insulin release during refeeding. RESULTS: Liver-based rescuing of CEACAM1 restored insulin clearance, plasma insulin level, insulin sensitivity and steatohepatitis caused by global deletion of Cc1. It also reversed the gain in body weight and total fat mass observed with Cc1 deletion, in parallel to normalising energy balance. Mechanistically, reversal of hyperphagia appeared to result from reducing fatty acid synthase activity and restoring insulin signalling in the hypothalamus. CONCLUSIONS/ INTERPRETATION: Despite the potential confounding effects of deleting Cc1 from extrahepatic tissues, liver-based rescuing of CEACAM1 resulted in full normalisation of the metabolic phenotype, underscoring the key role that CEACAM1-dependent hepatic insulin clearance pathways play in regulating systemic insulin sensitivity, lipid homeostasis and energy balance.
AIMS/HYPOTHESIS: The carcinoembryonic antigen-related cell adhesion molecule 1 (CEACAM1) promotes insulin clearance. Mice with global null mutation (Cc1 -/-) or with liver-specific inactivation (L-SACC1) of Cc1 (also known as Ceacam1) gene display hyperinsulinaemia resulting from impaired insulin clearance, insulin resistance, steatohepatitis and obesity. Because increased lipolysis contributes to the metabolic phenotype caused by transgenic inactivation of CEACAM1 in the liver, we aimed to further investigate the primary role of hepatic CEACAM1-dependent insulin clearance in insulin and lipid homeostasis. To this end, we examined whether transgenic reconstitution of CEACAM1 in the liver of global Cc1 -/- mutant mice reverses their abnormal metabolic phenotype. METHODS:Insulin response was assessed by hyperinsulinaemic-euglycaemic clamp analysis and energy balance was analysed by indirect calorimetry. Mice were overnight-fasted and refed for 7 h to assess fatty acid synthase activity in the liver and the hypothalamus in response to insulin release during refeeding. RESULTS: Liver-based rescuing of CEACAM1 restored insulin clearance, plasma insulin level, insulin sensitivity and steatohepatitis caused by global deletion of Cc1. It also reversed the gain in body weight and total fat mass observed with Cc1 deletion, in parallel to normalising energy balance. Mechanistically, reversal of hyperphagia appeared to result from reducing fatty acid synthase activity and restoring insulin signalling in the hypothalamus. CONCLUSIONS/ INTERPRETATION: Despite the potential confounding effects of deleting Cc1 from extrahepatic tissues, liver-based rescuing of CEACAM1 resulted in full normalisation of the metabolic phenotype, underscoring the key role that CEACAM1-dependent hepatic insulin clearance pathways play in regulating systemic insulin sensitivity, lipid homeostasis and energy balance.
Authors: Kitt Falk Petersen; Sylvie Dufour; David B Savage; Stefan Bilz; Gina Solomon; Shin Yonemitsu; Gary W Cline; Douglas Befroy; Laura Zemany; Barbara B Kahn; Xenophon Papademetris; Douglas L Rothman; Gerald I Shulman Journal: Proc Natl Acad Sci U S A Date: 2007-07-18 Impact factor: 11.205
Authors: Jiqian Huang; Kelly J Ledford; William B Pitkin; Lucia Russo; Sonia M Najjar; Helmy M Siragy Journal: Hypertension Date: 2013-06-03 Impact factor: 10.190
Authors: Garrett Heinrich; Lucia Russo; Tamara R Castaneda; Verena Pfeiffer; Hilda E Ghadieh; Simona S Ghanem; Jieshen Wu; Latrice D Faulkner; Süleyman Ergün; Marcia F McInerney; Jennifer W Hill; Sonia M Najjar Journal: J Biol Chem Date: 2016-03-21 Impact factor: 5.157
Authors: Roger H F Wong; Inhwan Chang; Carolyn S S Hudak; Suzanne Hyun; Hiu-Yee Kwan; Hei Sook Sul Journal: Cell Date: 2009-03-20 Impact factor: 41.582
Authors: Sumona Ghosh; Meenakshi Kaw; Payal R Patel; Kelly J Ledford; Thomas A Bowman; Marcia F McInerney; Sandra K Erickson; Raymond E Bourey; Sonia M Najjar Journal: Hepat Med Date: 2010-05
Authors: Qusai Y Al-Share; Anthony M DeAngelis; Sumona Ghosh Lester; Thomas A Bowman; Sadeesh K Ramakrishnan; Simon L Abdallah; Lucia Russo; Payal R Patel; Meenakshi K Kaw; Christian K Raphael; Andrea Jung Kim; Garrett Heinrich; Abraham D Lee; Jason K Kim; Rohit N Kulkarni; William M Philbrick; Sonia M Najjar Journal: Diabetes Date: 2015-05-13 Impact factor: 9.461
Authors: Garrett Heinrich; Hilda E Ghadieh; Simona S Ghanem; Harrison T Muturi; Khadijeh Rezaei; Qusai Y Al-Share; Thomas A Bowman; Deqiang Zhang; Robert S Garofalo; Lei Yin; Sonia M Najjar Journal: Front Endocrinol (Lausanne) Date: 2017-01-26 Impact factor: 5.555
Authors: Pablo Villa-Pérez; Beatriz Merino; Cristina M Fernández-Díaz; Pilar Cidad; Carmen D Lobatón; Alfredo Moreno; Harrison T Muturi; Hilda E Ghadieh; Sonia M Najjar; Malcolm A Leissring; Irene Cózar-Castellano; Germán Perdomo Journal: Metabolism Date: 2018-08-08 Impact factor: 8.694
Authors: Raghd Abu Helal; Harrison T Muturi; Abraham D Lee; Wei Li; Hilda E Ghadieh; Sonia M Najjar Journal: Int J Mol Sci Date: 2022-04-14 Impact factor: 6.208
Authors: Hilda E Ghadieh; Lucia Russo; Harrison T Muturi; Simona S Ghanem; Iyad H Manaserh; Hye Lim Noh; Sujin Suk; Jason K Kim; Jennifer W Hill; Sonia M Najjar Journal: Metabolism Date: 2019-01-19 Impact factor: 8.694
Authors: Raghd Abu Helal; Lucia Russo; Hilda E Ghadieh; Harrison T Muturi; Suman Asalla; Abraham D Lee; Cara Gatto-Weis; Sonia M Najjar Journal: Metabolism Date: 2021-05-28 Impact factor: 13.934
Authors: Hilda E Ghadieh; Harrison T Muturi; Lucia Russo; Christopher C Marino; Simona S Ghanem; Saja S Khuder; Julie C Hanna; Sukanta Jash; Vishwajeet Puri; Garrett Heinrich; Cara Gatto-Weis; Kevin Y Lee; Sonia M Najjar Journal: Hepatol Commun Date: 2017-11-02
Authors: Lucia Russo; Harrison T Muturi; Hilda E Ghadieh; Alexander M Wisniewski; Eric E Morgan; Syed S Quadri; Gavin P Landesberg; Helmy M Siragy; Guillermo Vazquez; Rosario Scalia; Rajesh Gupta; Sonia M Najjar Journal: Mol Metab Date: 2018-01-31 Impact factor: 8.568